[Role of protein carbamylation in chronic kidney disease complications].
Fiche publication
Date publication
juin 2015
Journal
Nephrologie & therapeutique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLERY Philippe
Tous les auteurs :
Gillery P, Jaisson S, Gorisse L, Pietrement C
Lien Pubmed
Résumé
Carbamylation corresponds to the non-enzymatic binding of isocyanic acid, mainly derived from urea decomposition, on amino groups of proteins, and participates in their molecular aging. This process is increased during chronic kidney disease (CKD) because of hyperuremia, and in other pathologies like atherosclerosis, where isocyanic may be formed from thiocyanate by myeloperoxidase in atheroma plates. Carbamylation triggers structural and functional modifications of proteins, thus impairing their biological roles and their interactions with cells. Much experimental evidence in vitro has shown the potential deleterious effects of carbamylated proteins on cell and tissue functions. Carbamylation-derived products (CDPs), and especially their major component homocitrulline, accumulate in organism in long half-life proteins, and may participate in the development of different complications of CKD, especially cardiovascular diseases, renal fibrosis, or nutritional and metabolic troubles. Recent clinical studies have confirmed the link between serum protein carbamylation and morbi-mortality in patients suffering from CKD or undergoing hemodialysis. Some CDPs could be used as biomarkers in these pathologies.
Mots clés
Biomarkers, Cardiovascular Diseases, etiology, Cyanates, metabolism, Fibrosis, Humans, Proteins, metabolism, Renal Insufficiency, Chronic, complications
Référence
Nephrol. Ther.. 2015 Jun;11(3):129-34